Celldex Therapeutics, Inc. (CLDX) Q1 2021 Earnings Results

Celldex Therapeutics Misses on EPS — Stock Down 4.01%

Celldex Therapeutics reported a larger-than-expected loss per share, which contributed to a 4.01% decline in stock price. The lack of revenue figures and forward guidance may raise concerns among investors about the company's near-term performance. The focus on clinical trials suggests that management is prioritizing long-term growth over immediate financial results.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.42	N/A	-31.25%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the challenges faced this quarter. They emphasized their commitment to advancing their clinical programs despite the EPS miss.

Management did not provide specific insights on revenue expectations.

The company is focused on ongoing clinical trials and product development.

Celldex Therapeutics Misses on EPS — Stock Down 4.01%

Key numbers

Management commentary

Celldex Therapeutics, Inc.

More earnings this week

Celldex Therapeutics Misses on EPS — Stock Down 4.01%

Key numbers

Management commentary